Increasing numbers of patients with coronary artery disease (CAD) are treated with dual antiplatelet therapy (DAPT) comprising aspirin and a P2Y12 inhibitor to reduce adverse events such as myocardial infarctions, ischemic strokes, and cardiovascular death [1,2]. Here, P2RY12 is linked to coronary artery disorder.